Cipla Limited — Important, 20-02-2025: Product launch

Cipla Ltd. has announced a board meeting to discuss the final approval received from the USFDA for its New Drug Application for Nilotinib Capsules (50, 150, and 200 mg), indicated for the treatment of Philadelphia chromosome positive chronic myeloid leukemia (CML). The product is anticipated to launch in FY 2025-26 in the US market. This approval enhances Cipla's oncology portfolio and positions the company for potential revenue growth, positively influencing investor sentiment. The entry into the US oncology market represents a significant opportunity amid competitive pressures.